STOCK TITAN

Cue Biopharma Announces Proposed Public Offering

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, has announced a proposed public offering of common stock shares and accompanying warrants. The offering includes the option for pre-funded warrants to purchase common stock. Oppenheimer & Co is acting as the sole book-running manager, with Newbridge Securities as co-manager.

The offering is subject to market conditions, and details regarding size and terms are not yet finalized. A shelf registration statement for this offering has been filed with the SEC and declared effective. The company will make the offering available through a prospectus supplement and accompanying prospectus.

Cue Biopharma (Nasdaq: CUE), un'azienda biofarmaceutica in fase clinica, ha annunciato una proposta di offerta pubblica di azioni ordinarie e relativi warrant. L'offerta include l'opzione per warrant pre-finanziati per l'acquisto di azioni ordinarie. Oppenheimer & Co funge da unico gestore della registrazione, con Newbridge Securities come co-gestore.

L'offerta è soggetta alle condizioni di mercato e i dettagli riguardanti la dimensione e i termini non sono ancora stati definiti. È stata presentata una dichiarazione di registrazione per questa offerta alla SEC, che è stata dichiarata efficace. L'azienda renderà l'offerta disponibile attraverso un supplemento al prospetto e un prospetto accompagnatorio.

Cue Biopharma (Nasdaq: CUE), una compañía biofarmacéutica en etapa clínica, ha anunciado una propuesta de oferta pública de acciones ordinarias y warrants asociados. La oferta incluye la opción de warrants prefinanciados para adquirir acciones ordinarias. Oppenheimer & Co actúa como el único gerente de libro, con Newbridge Securities como co-gerente.

La oferta está sujeta a las condiciones del mercado y los detalles sobre el tamaño y los términos aún no están finalizados. Se ha presentado una declaración de registro para esta oferta a la SEC y ha sido declarada efectiva. La compañía hará disponible la oferta a través de un suplemento de prospecto y un prospecto correspondiente.

큐 바이오파마(Nasdaq: CUE), 임상 단계의 바이오제약 회사, 는 보통주 및 관련 워런트에 대한 공개 모집 제안을 발표했습니다. 이 모집에는 보통주를 구매할 수 있는 선불 워런트 옵션이 포함되어 있습니다. 오펜하이머 & Co는 단독 주관 관리자 역할을 하며, 뉴브릿지 증권은 공동 관리자입니다.

이 제안은 시장 상황에 따라 달라지며, 규모 및 조건에 대한 세부 사항은 아직 최종화되지 않았습니다. 이 제안을 위해 SEC에 선반 등록 인수가 제출되었으며, 효력이 발생했습니다. 회사는 보충 prospectus와 함께 이 제안을 제공합니다.

Cue Biopharma (Nasdaq: CUE), une entreprise bio-pharmaceutique en phase clinique, a annoncé une offre publique proposée d'actions ordinaires et de warrants associés. L'offre comprend l'option de warrants préfinancés pour acheter des actions ordinaires. Oppenheimer & Co agit en tant que seul gestionnaire de livre, avec Newbridge Securities comme co-gestionnaire.

L'offre est soumise aux conditions de marché, et les détails concernant la taille et les termes ne sont pas encore finalisés. Une déclaration d'enregistrement de cette offre a été déposée auprès de la SEC et déclarée effective. L'entreprise mettra l'offre à disposition par le biais d'un supplément d prospectus et d'un prospectus accompagnant.

Cue Biopharma (Nasdaq: CUE), ein Unternehmen im klinischen Stadium der Biopharmazeutik, hat eine vorgeschlagene Börseneinführung von Stammaktien und begleitenden Warrants angekündigt. Das Angebot umfasst die Option auf vorfinanzierte Warrants zum Kauf von Stammaktien. Oppenheimer & Co fungiert als alleiniger Buchführer, während Newbridge Securities als Co-Manager auftritt.

Das Angebot unterliegt den Marktbedingungen, und Einzelheiten zu Größe und Bedingungen sind noch nicht finalisiert. Eine Shelf-Registrierungsanmeldung für dieses Angebot wurde bei der SEC eingereicht und für wirksam erklärt. Das Unternehmen wird das Angebot über einen Prospektzusatz und einen begleitenden Prospekt zur Verfügung stellen.

Positive
  • Potential to raise capital for company operations and development
  • Offering includes warrants, which may attract investors looking for additional upside potential
Negative
  • Potential dilution of existing shareholders' ownership
  • Uncertainty regarding the offering size and terms
  • Market conditions may affect the success of the offering

Insights

Cue Biopharma's announcement of a proposed public offering is a significant development for the company. This move suggests that the company is seeking to raise capital, likely to fund ongoing clinical trials or expand its research and development efforts. For a clinical-stage biopharmaceutical company with a market cap of just $22.7 million, this offering could substantially impact its financial position.

Key points to consider:

  • The offering includes common stock and warrants, which could lead to dilution for existing shareholders.
  • The involvement of Oppenheimer & Co. as the sole book-running manager lends credibility to the offering.
  • The use of a shelf registration statement indicates that the company had anticipated the need for additional capital.
  • The success and pricing of this offering will be important indicators of investor confidence in Cue Biopharma's pipeline and potential.

While raising capital can provide necessary funds for growth, it's important to monitor how effectively the company utilizes these resources to advance its clinical programs and create value for shareholders.

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.

Oppenheimer & Co. is acting as sole book-running manager for the offering. Newbridge Securities Corporation is acting as co-manager for the offering.

A shelf registration statement on Form S-3 (File No. 333-271786) relating to the securities to be offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) on May 9, 2023, and declared effective on May 26, 2023. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained by contacting: Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the proposed public offering, including the completion of the public offering on the anticipated terms, or at all. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would” or other comparable terms, although not all forward-looking statements contain these identifying words.

Cue Biopharma may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Cue Biopharma makes as a result of various risks and uncertainties, including but not limited to market and other financial conditions, satisfaction of customary closing conditions related to the proposed public offering, Cue Biopharma’s limited operating history, limited cash and a history of losses, Cue Biopharma’s ability to achieve profitability, potential setbacks in Cue Biopharma’s research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or Cue Biopharma’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates and other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of Cue Biopharma’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q. Any forward-looking statement made by Cue Biopharma in this press release is based only on information currently available to Cue Biopharma and speaks only as of the date on which it is made. Cue Biopharma undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Contact
Marie Campinell 
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com


FAQ

What is the purpose of Cue Biopharma's (CUE) proposed public offering?

Cue Biopharma's proposed public offering aims to raise capital, likely to fund ongoing operations, research, and development of their novel therapeutic biologics for T cell modulation.

Who are the underwriters for Cue Biopharma's (CUE) public offering?

Oppenheimer & Co is acting as the sole book-running manager for the offering, while Newbridge Securities is serving as co-manager.

What securities are being offered in Cue Biopharma's (CUE) public offering?

Cue Biopharma is offering shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase shares of common stock.

When was the shelf registration statement for Cue Biopharma's (CUE) offering filed and declared effective?

The shelf registration statement was filed with the SEC on May 9, 2023, and declared effective on May 26, 2023.

Cue Biopharma, Inc.

NASDAQ:CUE

CUE Rankings

CUE Latest News

CUE Stock Data

92.12M
60.21M
0.55%
26.71%
3.23%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON